Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
NASDAQ:INMB
INMB Stock Chart & Stats
$1.49
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.49
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.38 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)438.10K
Market Cap
$40.68M
Enterprise Value$28.38M
Total Cash (Recent Filing)$27.73M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 26, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding26,585,258
10 Day Avg. Volume339,530
30 Day Avg. Volume438,104
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.90
Price to Sales (P/S)6652.75
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue567.55
Enterprise Value/Gross Profit1.29K
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$8.00Price Target Upside436.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing AdvancementsINmune has successfully completed two commercial pilot-scale manufacturing runs of CORDSTROM at a UK facility, de-risking scale-up and supporting upcoming regulatory filings.
Platform ProgramsThe company continues to advance its platform programs, with primary focus on CORDSTROM, its mesenchymal stromal cell (MSC) therapy demonstrating clinical potential in recessive dystrophic epidermolysis bullosa (RDEB).
Regulatory ProgressOn the XPro program, the company remains on track to request an End-of-P2 meeting with the FDA, potentially occurring soon, which could provide guidance for a path forward and potentially supporting partnership discussions.
Bears Say
Financial LimitationsThe MINDFul trial was limited by financial resources, marking another failure of anti-inflammatory approaches in the treatment of AD.
Market CompetitionThe therapeutic area of later-line prostate cancer is crowded, and current drugs are very effective, making it difficult to find an ideal treatment slot for INKmune.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.38 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $40.68M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Feb 26, 2026 which is in 46 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Oct 30, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.078.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.24.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 5.78%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (436.91% Upside)
$8.00 (436.91% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.13%
12-Months-Change
Fundamentals
Return on Equity
-155.77%
Trailing 12-Months
Asset Growth
-36.80%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(436.91% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
11.17%
Insiders
4.48% Mutual Funds
1.10% Other Institutional Investors
77.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---